Antidepressant Therapy in Patients with Cancer: A Clinical Review

10.4103/TPSY.TPSY_3_19

Shen-Chieh Chang；Winston W. Shen

Anorexia/cachexia ； fatigue ； nausea ； pain

台灣精神醫學

33卷1期（2019 / 03 / 01）

13 - 19

英文

Background: The prevalence of major depressive disorder (MDD) by DSM criteria among cancer patients is about 14%-15% in oncological, hematological, and palliative services and the number is risen up to 20%-25% when other depressive disorders are also included. Like MDD patients in general, patients with cancer are thought to be underdiagnosed and undertreated. Untreated depression in cancer patients may lead to having distressed symptoms and signs, decreased quality of life, higher suicide risk, greater psychological burden on the family, longer hospital stays, poorer anticancer treatment compliance, as well as even increased risk for mortality. Methods: In this review, the authors reviewed published articles on the use of antidepressant use for patients with cancer, to familiarize the readers with the use of antidepressants. Results: Antidepressants have been found to be more effective than placebo in relieving depressive symptoms in patients with cancer, and the efficacy is positively associated with length of treatment. Although the rate of antidepressant prescription is increasing, still about 75% of cancer patients with depression have not yet received antidepressant treatment. Besides the use in treating mood and anxiety symptoms, antidepressants have also been found to have versatile rôles as palliative treatment for cancer‑related symptoms - pain, hot flushes, nausea, anorexia/cachexia, and fatigue. Furthermore, antidepressants have been studied for their anticancer potentials. They can inhibit tumor growth through either indirectly regulating immunity by enhancing cytotoxic activity and modulating cytokine production, or directly initiating cancer cell death and arresting cancer cell proliferation. We also found important drug-drug interaction between antidepressants and tamoxifen. Conclusion: Besides treating depressive and anxiety disorders, antidepressants are effective in treating cancer-related symptoms (pain, hot flushes, nausea, anorexia/cachexia, and fatigue). Cancer patients are eager to receive more effective treatment against their cancer as well as comorbid depression, and physicians should be more aggressive in providing every beneficial regimen - including an antidepressant.

1. Chen, CY,Chiu, YH,Shen, WW(2018).Drug augmentation for treatment-refractory major depressive disorder.Taiwan J Psychiatry,32,188-199.
   連結：
2. Adelson, KB,Loprinzi, CL,Hershman, DL(2005).Treatment of hot flushes in breast and prostate cancer.Expert Opin Pharmacother,6,1095-1106.
3. Ahmadian, E,Eftekhari, A,Babaei, H(2017).Anti-cancer effects of citalopram on hepatocellular carcinoma cells occur via cytochrome C release and the activation of NF-kB.Anticancer Agents Med Chem,17,1570-1577.
4. Antonijevic, IA(2006).Depressive disorders – Is it time to endorse different pathophysiologies?.Psychoneuroendocrinology,31,1-5.
5. Argilés, JM,Busquets, S,Stemmler, B(2014).Cancer cachexia: understanding the molecular basis.Nat Rev Cancer,14,754-762.
6. Bai, J,Li, Y,Zhang, G(2017).Cell cycle regulation and anticancer drug discovery.Cancer Biol Med,14,348-362.
7. Balkwill, F,Mantovani, A(2014).Inflammation and cancer: back to Virchow?.Lancet,357 27,539-545.
8. Ballin, A,Gershon, V,Tanay, A(1997).The antidepressant fluvoxamine increases natural killer cell counts in cancer patients.Isr J Med Sci,33,720-723.
9. Bennett, MI(2017).Mechanism-based cancer-pain therapy.Pain,Suppl 1,74-78.
10. Bennett, MI,Rayment, C,Hjermstad, M(2012).Prevalence and aetiology of neuropathic pain in cancer patients: a systematic review.Pain,153,359-365.
11. Berger, AM,Mooney, K,Alvarez-Perez, A(2015).Cancer-related fatigue, version 2.2015.Natl Compr Canc Netw,13,1012-1039.
12. Biglia, N,Bounous, VE,Susini, T(2018).Duloxetine and escitalopram for hot flushes: efficacy and compliance in breast cancer survivors.Eur J Cancer Care (Engl),27,e12484.
13. Biglia, N,Kubatzki, F,Sgandurra, P(2007).Mirtazapine for the treatment of hot flushes in breast cancer survivors: a prospective pilot trial.Breast J,13,490-495.
14. Bowie, M,Pilie, P,Wulfkuhle, J(2015).Fluoxetine induces cytotoxic endoplasmic reticulum stress and autophagy in triple negative breast cancer.World J Clin Oncol,6,299-311.
15. Brenne, E,Loge, JH,Kaasa, S(2013).Depressed patients with incurable cancer: which depressive symptoms do they experience?.Palliat Support Care,11,491-501.
16. Chen, VC,Liao, YT,Yeh, DC(2016).Relationship between antidepressant prescription and breast cancer: a population based study in Taiwan.Psychooncology,25,803-807.
17. Chochinov, HM(2001).Depression in cancer patients.Lancet Oncol,2,499-505.
18. Chochinov, HM,Wilson, KG,Enns, M(1997).“Are you depressed?” screening for depression in the terminally ill.Am J Psychiatry,154,674-676.
19. Choi, JH,Jeong, YJ,Yu, AR(2017).Fluoxetine induces apoptosis through endoplasmic reticulum stress via mitogen-activated protein kinase activation and histone hyperacetylation in SK-N-BE(2)-M17 human neuroblastoma cells.Apoptosis,22,1079-1097.
20. Cloonan, SM,Williams, DC(2011).The antidepressants maprotiline and fluoxetine induce type II autophagic cell death in drug‑resistant Burkitt’s lymphoma.Int J Cancer,128,1712-1723.
21. Cordero, MD,Sánchez‑Alcázar, JA,Bautista‑Ferrufino, MR(2010).Acute oxidant damage promoted on cancer cells by amitriptyline in comparison with some common chemotherapeutic drugs.Anticancer Drugs,21,932-944.
22. Cotterchio, M,Kreiger, N,Darlington, G(2000).Antidepressant medication use and breast cancer risk.Am J Epidemiol,151(6),951-957.
23. Dai, J,Liao, N,Shi, J(2017).Study of prevalence and influencing factors of depression in tumor patients and the therapeutic effects of fluoxetine.Eur Rev Med Pharmacol Sci,21,4966-4974.
24. Durand, JP,Deplanque, G,Montheil, V(2012).Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial.Ann Oncol,23,200-205.
25. Elmore, S(2007).Apoptosis: a review of programmed cell death.Toxicol Pathol,35,495-516.
26. Fang, CK,Chen, HW,Chiang, IT(2012).Mirtazapine inhibits tumor growth via immune response and serotonergic system.PLoS One,7,e38886.
27. Frick, LR,Rapanelli, M,Arcos, ML(2011).Oral administration of fluoxetine alters the proliferation/apoptosis balance of lymphoma cells and up-regulates T cell immunity in tumor-bearing mice.Eur J Pharmacol,659,265-272.
28. Gordon, P,LeGrand, SB,Walsh, D(2014).Nausea and vomiting in advanced cancer.Eur J Pharmacol,722,187-191.
29. Grassi, L,Nanni, MG,Rodin, G(2018).The use of antidepressants in oncology: a review and practical tips for oncologists.Ann Oncol,29,101-111.
30. Grond, S,Sablotzki, A(2004).Clinical pharmacology of tramadol.Clin Pharmacokinet,43,879-923.
31. Hanahan, D,Weinberg, RA(2011).Hallmarks of cancer: the next generation.Cell,144,646-674.
32. Haque, R,Shi, J,Schottinger, JE(2016).Tamoxifen and antidepressant drug interaction in a cohort of 16,887 breast cancer survivors.J Natl Cancer Inst,108,djv337.
33. Harlow, BL,Cramer, DW(1995).Self-reported use of antidepressants or benzodiazepine tranquilizers and risk of epithelial ovarian cancer: evidence from two combined case-control studies (Massachusetts, United States).Cancer Causes Control,6,130-134.
34. Hernández, ME,Mendieta, D,Martínez-Fong, D(2008).Variations in circulating cytokine levels during 52 week course of treatment with SSRI for major depressive disorder.Eur Neuropsychopharmacol,18,917-924.
35. Hutton, B,Yazdi, F,Bordeleau, L(2015).Comparison of physical interventions, behavioral interventions, natural health products, and pharmacologics to manage hot flashes in patients with breast or prostate cancer: protocol for a systematic review incorporating network meta-analyses.Syst Rev,4,114.
36. Jacob, L,Kostev, K,Kalder, M(2016).Treatment of depression in cancer and non-cancer patients in German neuropsychiatric practices.Psychooncology,25,1324-1328.
37. Jara, C,Del Barco, S,Grávalos, C(2018).SEOM clinical guideline for treatment of cancer pain (2017).Clin Transl Oncol,20,97-107.
38. Juurlink, D(2016).Revisiting the drug interaction between tamoxifen and SSRI antidepressants.BMJ,354,i5309.
39. Kannen, V,Hintzsche, H,Zanette, DL(2012).Antiproliferative effects of fluoxetine on colon cancer cells and in a colonic carcinogen mouse model.PLoS One,7,e50043.
40. Kelly, CM,Juurlink, DN,Gomes, T(2010).Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study.BMJ,340,c693.
41. Kinjo, T,Kowalczyk, P,Kowalczyk, M(2010).Effects of desipramine on the cell cycle and apoptosis in ca3/7 mouse skin squamous carcinoma cells.Int J Mol Med,25,861-867.
42. Kirkova, M,Tzvetanova, E,Vircheva, S(2010).Antioxidant activity of fluoxetine: studies in mice melanoma model.Cell Biochem Funct,28,497-502.
43. Kubera, M,Grygier, B,Arteta, B(2009).Age-dependent stimulatory effect of desipramine and fluoxetine pretreatment on metastasis formation by B16F10 melanoma in male C57BL/6 mice.Pharmacol Rep,61,1113-1126.
44. Kubera, M,Lin, AH,Kenis, G(2001).Anti‑inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio.J Clin Psychopharmacol,21,199-206.
45. Lee, HC,Chiu, WC,Wang, TN(2017).Antidepressants and colorectal cancer: a population-based nested case-control study.J Affect Disord,207,353-358.
46. Levkovitz, Y,Gil-Ad, I,Zeldich, E(2005).Differential induction of apoptosis by antidepressants in glioma and neuroblastoma cell lines: evidence for p-c-Jun, cytochrome c, and caspase-3 involvement.J Mol Neurosci,27,29-42.
47. Liou, GY,Storz, P(2010).Reactive oxygen species in cancer.Free Radic Res,44,479-496.
48. Martino, M,Rocchi, G,Escelsior, A(2012).Immunomodulation mechanism of antidepressants: interactions between serotonin/norepinephrine balance and Th1/Th2 balance.Curr Neuropharmacol,10,97-123.
49. Mathew, R,White, E(2011).Autophagy in tumorigenesis and energy metabolism: friend by day, foe by night.Curr Opin Genet Dev,21,113-119.
50. Ming-Hua, C,Bao-Hua, Z,Lei, Y(2016).Mechanisms of anorexia cancer cachexia syndrome and potential benefits of traditional medicine and natural herbs.Curr Pharm Biotechnol,17,1147-1152.
51. Mitchell, AJ,Chan, M,Bhatti, H(2011).Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies.Lancet Oncol,12,160-174.
52. Mittal, D,Gubin, MM,Schreiber, RD(2014).New insights into cancer immunoediting and its three component phases – Elimination, equilibrium and escape.Curr Opin Immunol,27,16-25.
53. Mohandas, H,Jaganathan, SK,Mani, MP(2017).Cancer-related fatigue treatment: an overview.J Cancer Res Ther,13,916-929.
54. Moss, EL,Simpson, JS,Pelletier, G(2006).An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners.Psychooncology,15,259-267.
55. Neufeld, NJ,Elnahal, SM,Alvarez, RH(2017).Cancer pain: a review of epidemiology, clinical quality and value impact.Future Oncol,13,833-841.
56. Nishida, N,Yano, H,Nishida, T(2006).Angiogenesis in cancer.Vasc Health Risk Manag,2,213-219.
57. Nishihara, M,Arai, YC,Yamamoto, Y(2013).Combinations of low-dose antidepressants and low-dose pregabalin as useful adjuvants to opioids for intractable, painful bone metastases.Pain Physician,16,E547-E552.
58. Okuyama-Tamura, M,Mikuni, M,Kojima, I(2003).Modulation of the human glucocorticoid receptor function by antidepressive compounds.Neurosci Lett,342,206-210.
59. Ostuzzi, G,Benda, L,Costa, E(2015).Efficacy and acceptability of antidepressants on the continuum of depressive experiences in patients with cancer: systematic review and meta-analysis.Cancer Treat Rev,41,714-724.
60. Pardini, M,Cordano, C,Benassi, F(2014).Agomelatine but not melatonin improves fatigue perception: a longitudinal proof-of-concept study.Eur Neuropsychopharmacol,24,939-944.
61. Park, EJ,Lee, JH,Jeong, DC(2015).Natural killer cell activity in patients with major depressive disorder treated with escitalopram.Int Immunopharmacol,28,409-413.
62. Park, EM,Raddin, RS,Nelson, KM(2014).Conducting an antidepressant clinical trial in oncology: challenges and strategies to address them.Gen Hosp Psychiatry,36,474-476.
63. Pearson, SA,Abrahamowicz, M,Srasuebkul, P(2015).Antidepressant therapy in cancer patients: initiation and factors associated with treatment.Pharmacoepidemiol Drug Saf,24,600-609.
64. Pinquart, M,Duberstein, PR(2010).Depression and cancer mortality: a meta-analysis.Psychol Med,40,1797-1810.
65. Portenoy, RK,Lesage, P(1999).Management of cancer pain.Lancet,353,1695-1700.
66. Qi, H,Ma, J,Liu, YM(2009).Allostatic tumor-burden induces depression-associated changes in hepatoma-bearing mice.J Neurooncol,94,367-372.
67. Riechelmann, RP,Burman, D,Tannock, IF(2010).Phase II trial of mirtazapine for cancer-related cachexia and anorexia.Am J Hosp Palliat Care,27,106-110.
68. Rossmanith, WG,Ruebberdt, W(2009).What causes hot flushes? the neuroendocrine origin of vasomotor symptoms in the menopause.Gynecol Endocrinol,25,303-314.
69. Sanjida, S,Janda, M,Kissane, D(2016).A systematic review and meta-analysis of prescribing practices of antidepressants in cancer patients.Psychooncology,25,1002-1016.
70. Schag, CA,Ganz, PA,Polinsky, ML(1993).Characteristics of women at risk for psychosocial distress in the year after breast cancer.J Clin Oncol,11,783-793.
71. Shen, WW(2016).Antidepressant therapy.Aino Journal (Osaka),15,1-13.
72. Shen, WW(2011).Clinical Psychopharmacology for The 21st Century.Taipei:Hochi Publishing Company.
73. Smith, EM,Pang, H,Cirrincione, C(2013).Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.JAMA,309,1359-1367.
74. Stepulak, A,Rzeski, W,Sifringer, M(2008).Fluoxetine inhibits the extracellular signal regulated kinase pathway and suppresses growth of cancer cells.Cancer Biol Ther,7,1685-1693.
75. Sukasem, C,Sirachainan, E,Chamnanphon, M(2012).Impact of CYP2D6 polymorphisms on tamoxifen responses of women with breast cancer: a microarray-based study in Thailand.Asian Pac J Cancer Prev,13,4549-4553.
76. Torta, RG,Ieraci, V(2013).Pharmacological management of depression in patients with cancer: practical considerations.Drugs,73,1131-1145.
77. Vazquez, A,Bond, EE,Levine, AJ(2008).The genetics of the p53 pathway, apoptosis and cancer therapy.Nat Rev Drug Discov,7,979-987.
78. Walker, J,Hansen, CH,Martin, P(2014).Prevalence, associations, and adequacy of treatment of major depression in patients with cancer: a cross-sectional analysis of routinely collected clinical data.Lancet Psychiatry,1,343-350.
79. Wu, CS,Lu, ML,Liao, YT(2015).Ovarian cancer and antidepressants.Psychooncology,24,579-584.
80. Xia, Z,Bergstrand, A,DePierre, JW(1999).The antidepressants imipramine, clomipramine, and citalopram induce apoptosis in human acute myeloid leukemia HL-60 cells via caspase-3 activation.J Biochem Mol Toxicol,13,338-347.
81. Xia, Z,Lundgren, B,Bergstrand, A(1999).Changes in the generation of reactive oxygen species and in mitochondrial membrane potential during apoptosis induced by the antidepressants imipramine, clomipramine, and citalopram and the effects on these changes by Bcl-2 and Bcl-X (L).Biochem Pharmacol,57,1199-1208.
82. Xiang, X,An, R,Gehlert, S(2015).Trends in antidepressant use among U.S. Cancer survivors, 1999-2012.Psychiatr Serv,66,564.
83. Yuan, SY,Cheng, CL,Ho, HC(2015).Nortriptyline induces mitochondria and death receptor-mediated apoptosis in bladder cancer cells and inhibits bladder tumor growth in vivo.Eur J Pharmacol,761,309-320.
84. Zaini, S,Guan, NC,Sulaiman, AH(2018).The use of antidepressants for physical and psychological symptoms in cancer.Curr Drug Targets,19,1431-1455.

1. Kao, Pei-Hsin,Jang, Fong-Lin(2019).The Potential Use of Using the Psychological Side Effects of Antidepressants in Treating Cancer Patients.臺灣精神醫學,33(4),227-228.